Shanghai MITRASSIST Medical Closes Nearly $100 Million Series C Financing

Shanghai-based MITRASSIST Medical has closed nearly $100 Million Series C Financing jointly led by Centurium Capital and 6 Dimensions Capital, followed by Shanghai Jiading State Capital, Hefei Haiheng Capital, Hefei Industry Investment Group, Anyuan Fund, and Binhu Science City.

The funds will mainly be used for the development and commercialization of mitral valve replacement products and aortic polymer valve products.

Founded in 2017, MITRASSIST Medical is committed to becoming a global leader in innovative cardiovascular medical devices, covering interventional heart valve therapy, interventional coronary drug balloon, and interventional heart failure therapy.

Just a week ago, MITRASSIST Medical signed an agreement with the local government to invest 2 billion yuan ($270 million) in Hefei City, Anhui Province, to build a base for research and development, production and commercialisation of cardiovascular products and high-value consumables, covering products such as non-invasive monitoring of heart failure and pulmonary water, drug balloon, and structural heart.

MITRASSIST Medical closed $70 million Series B financing led by Centurium Capital in December 2020.